MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202641043562 A) filed by Dr. Divya Ajmeera; Dr. Shanthipriya Ajmera; Prof. Sarangapani Manda; and Dr. Rajanna Ajumeera, Karimnagar, Telangana, on April 6, for 'sustained release matrix tablet formulation of nebivolol hydrochloride using a dual-polymer matrix and method of preparation thereof.'
Inventor(s) include Dr. Divya Ajmeera; Dr. Shanthipriya Ajmera; Prof. Sarangapani Manda; and Dr. Rajanna Ajumeera.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a sustained release oral matrix tablet formulation of Nebivolol Hydrochloride for prolonged and controlled drug delivery. The formulation comprises Nebivolol Hydrochloride uniformly dispersed within a polymeric matrix comprising hydroxypropyl methylcellulose (HPMC) and ethyl cellulose as matrix-forming polymers. The hydrophilic swelling property of hydroxypropyl methylcellulose and the hydrophobic diffusion-modulating property of ethyl cellulose cooperate to regulate the release of Nebivolol Hydrochloride through a combined mechanism of drug diffusion through the hydrated polymer matrix and gradual erosion of the polymer matrix. Upon contact with gastrointestinal fluids, hydroxypropyl methylcellulose hydrates to form a gel layer surrounding the tablet, while ethyl cellulose controls penetration of dissolution media and drug diffusion pathways. The formulation provides sustained drug release for approximately twelve hours following oral administration. The invention further provides a method for preparing the sustained release matrix tablet using blending, optional granulation, drying, and compression, suitable for large-scale pharmaceutical manufacturing for treatment of hypertension and related cardiovascular disorders."
Disclaimer: Curated by HT Syndication.
